What is the 13F Pro Quality Score for CVRX?

13F Pro ranks CVRx, Inc. (CVRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CVRX's current score at https://13fpro.ai/research/CVRX (free sign-up required for the full ranking).

Which hedge funds own the most CVRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CVRX include JOHNSON & JOHNSON, NEA Management Company,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CVRX as soon as new 13F filings post.

Where does 13F Pro source CVRX data?

All CVRx, Inc. fundamentals and ownership data come directly from SEC EDGAR. CVRx, Inc. files with the SEC under CIK 1235912. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CVRX in?

CVRx, Inc. (CVRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CVRX research updated on 13F Pro?

CVRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CVRx, Inc.(CVRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1235912 CVRX stock profile & AI dashboard →

13F Pro Quality Score

24.3/100

Rank #2,586 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

80.4/100

Profitability

7.5/100

Balance Sheet

3.1/100

Earnings Quality

30.0/100

Free Cash Flow

7.6/100

Institutional Flow

26.7/100

Revenue Scale

12.2/100

Dilution Risk

9.3/100

CVRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CVRx, Inc. (CVRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CVRX at 24.3/100 on a 32-signal composite quality model, placing it at rank #2,586 of 2,879 stocks — the bottom half of the AI-ranked universe. CVRX scores in the top quartile across revenue growth (80.4). Areas of concern include balance sheet strength (3.1) and profitability (7.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), CVRx, Inc. reports quarterly revenue of $14.8M, net income of $-13.1M, an operating margin of -82.3%. Top institutional holders of CVRX by reported 13-F value include JOHNSON & JOHNSON, NEA Management Company,, BlackRock,, based on the most recent SEC filings. CVRX trades on the Nasdaq exchange and files with the SEC under CIK 1235912. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CVRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CVRx, Inc. directly from SEC EDGAR. CVRx, Inc.'s 13F Pro composite quality score has ranged between 8 and 63 since 2022, currently 24.3 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about CVRx, Inc.

Quirks, history, and lore behind CVRX — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap medical device company · listed on Nasdaq · headquartered in Minnesota · focused on cardiovascular and renal disease.
2
The Numbers
Annual revenue in the low tens of millions of dollars — this is a commercial-stage company still scaling, not a household healthcare giant.
3
The History
Founded in the early 2000s, it spent years in development before receiving FDA approval and later gained a CE Mark for use in Europe as well.
4
The Secret
Its core technology works by electrically stimulating the carotid baroreceptor — essentially tricking the brain into lowering blood pressure without more pills.
5
The Lore
Its implantable device targets patients with resistant hypertension — people whose blood pressure won't budge despite taking three or more medications daily.
6
The Giveaway
The company's flagship product, the Barostim, is the only FDA-approved baroreflex activation therapy device — a pacemaker-like implant that tells your nervous system to chill out.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$14.8M

Net Income

Q1 2026

$-13.1M

Free Cash Flow

Q1 2026

$-12.3M

Operating Margin

Q1 2026

-82.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.4% YoY

$56.7MFY 2025

FY22 $22.5MFY23 $39.3MFY24 $51.3MFY25 $56.7M

Net Income

+11.1% YoY

$-53.3MFY 2025

FY22 $-41.4MFY23 $-41.2MFY24 $-60.0MFY25 $-53.3M

Operating Income

+13.8% YoY

$-51.3MFY 2025

FY22 $-42.5MFY23 $-43.1MFY24 $-59.5MFY25 $-51.3M

EPS (Diluted)

+23.0% YoY

$-2.04FY 2025

FY22 $-2.02FY23 $-0.43FY24 $-2.65FY25 $-2.04

Total Assets

-21.5% YoY

$104.8MFY 2025

FY22 $124.9MFY23 $115.2MFY24 $133.4MFY25 $104.8M

Total Debt

+0.5% YoY

$49.5MFY 2025

FY22 $6.7MFY23 $29.2MFY24 $49.3MFY25 $49.5M

Op. Cash Flow

-2.6% YoY

$-40.2MFY 2025

FY22 $-42.7MFY23 $-39.0MFY24 $-39.1MFY25 $-40.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$56.7M +10.4%	$51.3M +30.5%	$39.3M +74.9%	$22.5M +72.4%	$13.0M +115.4%	$6.1M
Net Income	$-53.3M +11.1%	$-60.0M -45.5%	$-41.2M +0.6%	$-41.4M +3.8%	$-43.1M -205.3%	$-14.1M
Operating Income	$-51.3M +13.8%	$-59.5M -38.0%	$-43.1M -1.4%	$-42.5M -63.8%	$-26.0M -125.5%	$-11.5M
EPS (Diluted)	$-2.04 +23.0%	$-2.65 -516.3%	$-0.43 +78.7%	$-2.02 +51.4%	$-4.16	—
Total Assets	$104.8M -21.5%	$133.4M +15.8%	$115.2M -7.8%	$124.9M -18.1%	$152.5M +135.5%	$64.8M
Total Debt	$49.5M +0.5%	$49.3M +68.6%	$29.2M +333.1%	$6.7M	$0.00 -100.0%	$19.3M
Operating Cash Flow	$-40.2M -2.6%	$-39.1M -0.3%	$-39.0M +8.6%	$-42.7M -53.9%	$-27.7M -72.3%	$-16.1M

AI Insight: CVRX Financial Trends

CVRx continues burning equity at an accelerating pace — book value has collapsed from $71M to $29M in just four quarters while losses persist.

• Revenue grew modestly from $12M in Q2 2024 to $16M in Q4 2025, but stalled at $15M in Q1 2026.

• Equity has eroded sharply from $71M in Q4 2024 to $29M in Q1 2026 — a 59% decline in four quarters.

• Operating losses have shown only marginal improvement, narrowing from -$14M in Q2 2024 to -$12M in Q1 2026.

• Total debt rose to $58M in Q1 2026, the highest in the dataset, up from $49M held steady across Q3 2024–Q4 2025.

⚠ Equity at $29M and falling — at current burn rates, the balance sheet may require dilutive capital raise within 2–3 quarters.

⚠ Operating cash outflow worsened to -$12M in Q1 2026 from -$10M in Q4 2025, reversing prior sequential improvement.

⚠ Debt jumped $9M to $58M in Q1 2026 — monitor whether further borrowing capacity exists to fund ongoing operations.

AI Insight: CVRX Ratio Trends

CVRx remains deeply loss-making: operating margins stuck in the -70% to -118% range and D/E spiked to 2.01x in Q1 2026, signaling accelerating balance-sheet stress.

• Operating margin improved from -118.3% in Q2 2024 to -69.8% in Q4 2025, but reversed to -82.3% in Q1 2026.

• D/E ratio surged from 0.53 in Q2 2024 to 2.01 in Q1 2026, more than tripling leverage over six quarters.

• ROE deteriorated sharply to -180.3% in Q1 2026 from -60.0% in Q4 2024, reflecting deepening equity erosion.

⚠ D/E at 2.01x in Q1 2026 is the highest in the dataset; further debt accumulation could threaten liquidity runway.

⚠ Operating margin improved sequentially through Q4 2024 then stalled — monitor whether Q2 2026 resumes improvement.

⚠ ROIC of -55.5% in Q1 2026 versus -34.2% in Q4 2024 suggests capital deployment efficiency is worsening, not improving.

Get alerted when CVRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CVRx, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CVRX

JOHNSON & JOHNSON
$38.1M4,024,861 sh
NEA Management Company, LLC
$19.2M2,026,083 sh
BlackRock, Inc.
$9.7M1,026,559 sh
GSK plc
$9.5M1,007,583 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.6M911,310 sh
ROYAL BANK OF CANADA
$6.7M706,950 sh
BALYASNY ASSET MANAGEMENT L.P.
$6.0M630,812 sh
SILVERCREST ASSET MANAGEMENT GROUP LLC
$5.4M572,021 sh
Parkman Healthcare Partners LLC
$4.1M429,507 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.0M427,072 sh

Fund	Value	Shares
JOHNSON & JOHNSON	$38.1M	4,024,861
NEA Management Company, LLC	$19.2M	2,026,083
BlackRock, Inc.	$9.7M	1,026,559
GSK plc	$9.5M	1,007,583
VANGUARD CAPITAL MANAGEMENT LLC	$8.6M	911,310
ROYAL BANK OF CANADA	$6.7M	706,950
BALYASNY ASSET MANAGEMENT L.P.	$6.0M	630,812
SILVERCREST ASSET MANAGEMENT GROUP LLC	$5.4M	572,021
Parkman Healthcare Partners LLC	$4.1M	429,507
GEODE CAPITAL MANAGEMENT, LLC	$4.0M	427,072

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CVRX on your watchlist

Track score changes the day CVRx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CVRX a good stock to buy?

13F Pro's AI-powered analysis of CVRx, Inc. (CVRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CVRX are available on the CVRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CVRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CVRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CVRx, Inc.'s investment landscape.